Cite
HARVARD Citation
Eichhorst, B. et al. (n.d.). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet oncology. 17 (7), pp. 928-942. [Online].